It looks like you're new here. If you want to get involved, click one of these buttons!
div>The contrasting conclusions of these studies, summarized in Tables 1 and 2, are probably because of the different study designs, ethnicities of the study populations, differences in the prevalence of advanced fibrosis and different schedules of RBV. However, a recent meta-analysis (8), including all the above-mentioned studies, found that 24 weeks of therapy should remain the standard duration for G2 and low-viraemic G3 patients. The subgroup analysis of these results also suggested that SVR rates were similar in patients who achieved RVR independent of basal viral load whether they had received standard or short-term treatment. Another recent meta-analysis (18) also compared the results of short therapy and standard therapy in G2 and G3 patients. This study concluded that short therapy does not reduce the efficacy of treatment in G2 and G3 CHC patients who achieve A-1155463 datasheet RVR, while patients who do not should consider 24 weeks of treatment. learn more However, overall, the results of these meta-analyses as well as the individual studies need to be confirmed in large studies before being applied to clinical practice, especially in patients with G3, HVL, obesity and advanced fibrosis. Mangia et al. (19) recently reported that both G2 and G3 patients with RVR who relapsed after 12 weeks of treatment achieved SVR in 70% of cases when retreated for 24 weeks. In addition, all of the above studies and the meta-analysis showed that only about 50% of G2 and G3 patients who did not achieve RVR achieved SVR even after 24 weeks of treatment, suggesting that longer treatment could be indicated. However, randomized-controlled trials (RCT) are needed before suggesting prolonged treatment Palbociclib in this cohort of patients. Predictive factors of achieving SVR and RVR are of major relevance to identify G2 and G3 CHC patients who could benefit from a shorter regimen. The results of published studies are summarized in Table 3. As expected, most of the predictive factors of SVR with standard treatment have been revalidated for shorter therapies. Dalgard et al. (9) showed that absent or minimal fibrosis was strongly predictive of achieving SVR in all patients treated for 12 or 24 weeks, even if 29 patients were excluded from the analysis because of a lack of histological data. Interestingly, the authors found that age <40 years old and HCV-RNA <600?000?IU were the strongest independent baseline predictors of SVR when considering all patients, without evaluating histological data. Similar data have been reported in the other studies. In particular, the ACCELERATE study (13) found that younger age, LVL and the absence of severe fibrosis were independent baseline predictors of SVR in the entire population, but also found that other factors played a role such as lower body weight, higher ALT levels and G2 infection.</div>